Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade

CONCLUSIONS: Here, the authors have provided a transcriptomic analysis of a progression cohort for IDH-mutant glioma. Compared with lower-grade tumors, grade 4 astrocytomas displayed alterations that may inform the timing of antiangiogenic and immune-based therapy as these tumors progress.PMID:38301244 | DOI:10.3171/2023.11.FOCUS23694
Source: Neurosurgical Focus - Category: Neurosurgery Authors: Source Type: research